Sitemap

• The Galapagos Group
  • Letter from the CEO
  • At a glance
  • Strategy
  • Overview of Galapagos NV
  • Going concern statement
  • Risk management
  • The Galapagos share
  • Subsequent events
  • Disclaimer and other information
• R&D
  • The Galapagos pipeline
  • Target discovery
  • Rheumatoid arthritis
  • Inflammatory bowel disease
  • Cystic fibrosis
  • IPF
• Risk factors
  • Financial position and need for additional capital
  • Product development, regulatory approval and commercialization
  • Reliance on third parties
  • Competitive position
  • Intellectual property
  • Organization, structure and operation
  • Galapagos shares
  • General statement
• Corporate governance
  • Policies
  • Board of Directors
  • Committees
  • Share capital and shares
  • Shareholders
  • Remuneration report
    • Determination
    • Policy
    • Non-executive Directors
    • Executive Directors
    • Criteria and methods to evaluate performance
    • Gross remuneration of CEO
    • Gross remuneration of other Executive Committee members
    • Shares, warrants or other rights
    • Contractual provisions
    • Severance payments
    • Claw-back right
  • Conflict of interests and related parties
  • Statement by the Board of Directors
• Financial statements
  • Consolidated financial statements
    • Income statement and statement of comprehensive income
    • Statements of financial position
    • Cash flow statements
    • Statements of changes in equity
  • Non-consolidated financial statements
• Notes
  • Notes to the consolidated financial statements
    • Notes 1-10
      • 1. General Information
      • 2. Significant accounting policies
      • 3. Segment information
      • 4. Total revenues and other income
      • 5. Operating costs
      • 6. Staff costs
      • 7. Finance income and expense
      • 8. Taxes
      • 9. Discontinued operations
      • 10. Result per share
    • Notes 11-20
      • 11. Goodwill
      • 12. Intangible assets
      • 13. Property, plant and equipment
      • 14. Research and Development incentives receivables
      • 15. Other non-currrent assets
      • 16. Restricted cash
      • 17. Inventory
      • 18. Trade and other receivables and other current assets
      • 19. Cash and cash equivalents
      • 20. Share capital
    • Notes 21-30
      • 21. Share premium
      • 22. Other reserves
      • 23. Translation differences
      • 24. Deferred tax
      • 25. Finance lease liabilities
      • 26. Trade and other payables
      • 27. Provisions
      • 28. Operating lease obligations
      • 29. Off-balance sheet arrangements
      • 30. Contingent assets and liabilities
    • Notes 31-40
      • 31. Retirement benefit plans
      • 32. Warrant plans
      • 33. Related parties
      • 34. Remuneration of key management personnel
      • 35. Consolidated companies as of 31 December 2014
      • 36. Company acquistions and disposals
      • 37. Critical accounting estimates and judgments
      • 38. Financial risk management
      • 39. Auditor’s remuneration
      • 40. Events after balance sheet date
  • Report of the statutory auditor